PTO/SB/08b (01-08)

Approved for use through 07/31/2008. OMB 0651-0031
S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons and Substitute for form 1449/PTC				U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE re required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
Gallouis	10 10 10111 14-24 10			Application Number	10/584,930	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	March 31, 2008	
				First Named Inventor	Nilsson	
				Art Unit		
(cools many sheets to meets tally)				Examiner Name		
Sheet	3	of	3	Attorney Docket Number	34112-002	

		NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
		Watts, et al., "Functionalised 2,3-dimethyl-3-aminotetrahydrofuren-4-one and N-(3-oxo- hexahydrocyclopenta[b]furen-3e-yl)acylamide based scaffolds: synthesis and cysteinyl proteinase inhibition", Bioorganic and Medicinal Chemistry, 2004 12:2903-2925				
		Ouibell, "Bicyclic peptidomimetic tetrahydrofuro[3,2-b]pyrrol-3-one and hexahydrofuro[3,2-b]pyridine-3-one based scaffolds: synthesis and nusteinvl proteinase inhibition", Bioorganic a Medicinal Chemistry, 2004 12:5699-5710				
		International Search Report (Form PCT/ISA/210)				
		Written Opinion Of The Searching Authority (Form PCT/ISA/237)				
-						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

continuement includes days of with form wan nex consummation as appearant. Journal of the properties o